Radius Recycling, Inc.

Good day and thank you for standing by. Welcome to the Radius Health Incorporated First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone keypad. Please be advised that today's conference is being recorded. If you require any further assistance, please press star 0. I would now like to hand the conference over to Ethan Holdaway, Head of Investor Relations. Sir, you may begin the conference.

Thank you. Hello, everyone, and thanks for joining us today. A press release and presentation that we'll use to guide the discussion can be found in the Investor Relations section of our website. A replay will also be available on our website following the call. Before we begin, I'd like to remind everyone of our safe harbor statement on page two. This presentation includes forward-looking statements and non-GAAP financial measures. You can find the reconciliation of GAAP to non-GAAP at the end of the presentation. Our most recently filed 10-K and subsequent filings identify factors that could cause our actual results to differ materially from those indicated by the forward-looking statements. Any forward-looking statements represent our views as of today only. Kelly Martin, President and CEO, will kick off the call with his opening comments. Mark Conley, Chief Financial Officer, will then provide a financial update. Bob Valentine, Head of Commercial Business Intelligence, will follow with a commercial update. Chaya Shah, SVP of Abalapartheid and Elastostrom, will provide an update on Abalapartheid and Elastostrom progress. And Liz Messersmith, SVP of Neuroscience Group, will finish up with an update on RAD11. We will then open up the call for questions. I'd now like to turn it over to Kelly.

Thank you, Ethan. We appreciate everyone taking time to spend a few moments with us this morning. We realize there's a tremendous amount of things going on in the market broadly and with individual companies. For the second earnings in a row, I have a rather expansive quote in the announcement, which if you haven't read it, I'd point you to. It goes through a fair amount of topics that we believe are important to emphasize to the marketplace. After my opening comments, I'll turn the call to Mark, our Chief Financial Officer, and then after his comments, he'll turn it to the rest of the team. We've all worked very hard on this earnings call for preparation for this earnings call. And our goal is to make sure that you have an up to the date assessment and information with regard to all public information that is important to share. My comments will be focused for the next few minutes on the broad framework of the rest of the meeting. First and foremost, we continue to manage the company on an integrated basis. We listed talent there. The market is super hot for talent. Our retention of talent is a very important topic, and our specific recruitment of talent continues to be something that we all have to work on and focus on as the talent market in biotech is super hot, particularly for certain functions. You'll hear from Mark on the balance sheet. You'll hear from the team on the assets. But from a financial and balance sheet point of view, The interrelationship between timelines, spend, and revenue is something that we manage and monitor on a daily, weekly, and monthly basis. Tim Los, our core revenue-producing asset, our main focus is rather simple. How do we maximize the cash flow generation in the U.S. for the SC product? We have talked in the past about ex-U.S. extending the footprint. You'll hear from Shia and Bob on that. And very importantly, preparing for the U.S. mail launch. Mail market, from a denominator point of view, is anywhere from 10 to 25 more patients, 10 to 25 percent more patients. The information that we have gleaned from the marketplace, from KOLs and from investigators and clinicians, is that the The need on the male side of the equation, if anything, is more severe than female. Our challenge commercially in marketing is how do you get to them in an efficient manner, and you'll hear from Bob on that to some degree later. Elastostrand, and more importantly, the surge space is certainly one that continues to provide a plethora of information, of data, of updates. Since our last discussion, there was another – failure in the space, in the surge space. Now that both Sanofi and Roche have, for whatever reasons, failed to hit their pre-specified endpoints, we await, with our partner, Manarini, on the output from both Lilly and AstraZeneca over the next six months. But in the meantime, we remain resolutely focused on moving Elastostrand forward. You'll hear from Shia on that. We work very closely closely with Manarini on all aspects of this asset. The market opportunity, as we make progress against our regulatory and go-to-market plans, and others have not had success, obviously the market opportunity potentially is expanding before us, and that's something that we're very focused on. Lastly, around Elastostrand, our internal values of Elastostrand And from a risk-adjusted basis, obviously risk is going, in our model, down, probability going up. And if you look at the totality of potential cash flows at different revenue, I would just say it's a very interesting asset for us, even with our financial participation. RAD 011, you'll hear from Liz a bit later. In a very disciplined manner, we expect to continue to move this asset forward. It's an asset that we share. aired for two, two and a half hours in an R&D meeting in early April, April 5th to be specific. We had lots of back and forth after that meeting with various people. I think the science, the technology, and the patient need and opportunity there continues to be one that we view as attractive, and you'll hear from Liz on that later. Last but not least, and tying back to Elastostrand, we had announced previously that all of the capital from Elastistrand, however we may receive it over time, would be returned to stakeholders, both creditors and shareholders. And in so doing, we would certainly be able to utilize more strategically the NOLs that have built up in the company over the years. So that's at a high level. Things that we remain focused on, again, I point you back to my quote, rather unusual for me to even have a quote, but certainly one that's reasonably long. very specifically mentions a bunch of different things. So with that, I'm going to turn it over to our Chief Financial Officer, Mark Conley, and Mark will take you through the financial aspects of the company. And then towards the end of the call, we certainly look forward to any questions you might have.